For research use only. Not for therapeutic Use.
Zolimidine, a derivate of imidazopyridine, is an orally active antiulcer agent. Zolimidine stimulates mucus secretion in intestinal mucosal cells and enhacnes intestinal wall more resistant to ulceration. Zolimidine exhibits gastroprotective effect in duodenal ulcer research[1][2].
Zolimidine (200 mg/kg; po) reduces the incidence of intestinal ulcers induced by Indomethacin (HY-14397) (5 mg/kg/day for 8 days, rectally) in rats[2].
Zolimidine (1% in the diet) decreases the incidence of intestinal ulcers caused by carrageenan (5% in the drinking water, for 40 days) in guinea pigs[2].
Catalog Number | M049026 |
CAS Number | 1222-57-7 |
Synonyms | 2-(4-methylsulfonylphenyl)imidazo[1,2-a]pyridine |
Molecular Formula | C14H12N2O2S |
Purity | ≥95% |
InChI | InChI=1S/C14H12N2O2S/c1-19(17,18)12-7-5-11(6-8-12)13-10-16-9-3-2-4-14(16)15-13/h2-10H,1H3 |
InChIKey | VSLIUWLPFRVCDL-UHFFFAOYSA-N |
SMILES | CS(=O)(=O)C1=CC=C(C=C1)C2=CN3C=CC=CC3=N2 |
Reference | [1]. Belohlavek D, et al. The effect of zolimidine, imidazopyridine-derivate, on the duodenal ulcer healing. Scand J Gastroenterol Suppl. 1979;54:44. [2]. Carminati GM, et al. Protective action of zolimidine against two different types of experimental intestinal ulcers. Farmaco, Edizione Pratica (1978), 33(2), 68-79. |